AOD-9604 5 mg – Lipolytic HGH Fragment for Metabolic Research
⚠️ Warning: This product is intended solely for scientific research purposes (research use only). It is not intended for use as a medicine, drug, dietary supplement, or for human use. Sale restricted to individuals over the age of 18.
What is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide derived from the C-terminal fragment of human growth hormone (HGH)—specifically residues 176–191. Unlike native HGH, the N-terminal group is modified by the substitution of phenylalanine for tyrosine (Tyr→Phe), which fundamentally alters its pharmacological profile.
The peptide was originally developed by the Australian company Metabolic Pharmaceuticals Ltd. with the aim of isolating the lipolytic properties of HGH without its undesirable metabolic effects—specifically, without the diabetogenic and growth effects associated with the whole growth hormone molecule.
Origin and Development: Metabolic Pharmaceuticals Ltd.
Metabolic Pharmaceuticals Ltd. (Australia) has initiated a series of preclinical and clinical studies focused on research into adipose tissue metabolism. AOD-9604 has undergone Phase 2A clinical trials for obesity, making it one of the well-documented investigational compounds in its class.
Mechanism of Action in Research
Relationship to Growth Hormone (HGH)
Native HGH exhibits two distinct groups of biological activities: (1) growth and diabetogenic effects mediated by the N-terminal region of the molecule, and (2) lipolytic effects localized in the C-terminal fragment (residues 176–191). AOD-9604 is an isolated C-terminal fragment designed to preserve lipolytic activity without the growth-promoting and insulin-resistance-inducing effects of full-length HGH.
Beta-3 adrenergic receptors and lipolysis in adipose tissue
Preclinical studies suggest that AOD-9604 acts on beta-3 adrenergic receptors in adipose tissue. In in vitro and in vivo models (animal studies), the following was observed:
- Stimulation of lipolysis – mobilization of stored fat in adipocytes
- Inhibition of lipogenesis – suppression of the formation of new fat stores
These mechanisms have been studied primarily in animal models (mouse and rat models of obesity). The results from preclinical studies serve as the basis for further scientific research.
Clinical Research Status
FDA GRAS status and Phase 2A clinical trials (obesity)
AOD-9604 has been granted GRAS (Generally Recognized As Safe) status by the U.S. FDA for food use, which confirms its safety profile based on available scientific data.
As part of Metabolic Pharmaceuticals Ltd.’s clinical program, Phase 2A studies were conducted to investigate weight management in obese patients. The results of these studies are publicly available and form the basis for further research into lipolytic peptides.
Clinical status: AOD-9604 is not approved as a registered drug in the EU or in Slovakia. It is the subject of scientific research.
Technical Specifications and Storage
| Parameter | Value |
| Form | Freeze-dried powder |
| Quantity | 5 mg per bottle |
| Purity | ≥98% (HPLC verified) |
| CAS Number | 221231-10-3 |
| Molecular weight | 1,817.9 Da |
| Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe |
| Storage (long-term) | -20 °C (lyophilized) |
| Storage (after reconstruction) | 2–8 °C, use within 28 days |
| Reconstitution | Bacteriostatic water or sterile water |
Frequently Asked Questions About AOD-9604 (FAQ)
AOD-9604 is a synthetic fragment of human growth hormone (residues 176–191). Scientific research focuses on its lipolytic properties—its ability to stimulate the breakdown of adipose tissue in in vitro and in vivo models without the effects of full-length HGH.
FDA GRAS (Generally Recognized As Safe) is a status granted to substances considered safe based on available scientific data. This status has been granted to AOD-9604 for food use and demonstrates the safety profile of this compound.
Full-length growth hormone (HGH) has a wide range of metabolic effects, including growth-promoting and diabetogenic effects. AOD-9604 is an isolated C-terminal fragment that, according to preclinical studies, retains lipolytic properties without these undesirable effects.
The lyophilized powder should be reconstituted with bacteriostatic or sterile water. For exact volumes, use the dosing calculator at jacked.sk. Store the reconstituted solution at 2–8 °C and use within 28 days.
Each batch of AOD-9604 has a purity of ≥98%, as verified by HPLC (high-performance liquid chromatography). A Certificate of Analysis (COA) is available upon request.
AOD-9604, sold on jacked.sk, is intended exclusively for scientific research purposes. It is not classified as a controlled substance in Slovakia. The customer is responsible for complying with applicable laws in their jurisdiction.
⚠️ Warning – Intended exclusively for research purposes
All products sold on jacked.sk are intended EXCLUSIVELY for scientific research purposes. They are not intended for use as a medicine, drug, dietary supplement, or cosmetic product, nor for human or veterinary use. The results cited in the descriptions are based on preclinical studies (in vitro, animal models) and cannot be automatically extrapolated to human use. Sale restricted to individuals over the age of 18. By purchasing this product, the customer confirms that they are a professional researcher and will use the product solely in accordance with applicable laws.







